Insulet Corporation $PODD Shares Sold by Rafferty Asset Management LLC

Key Points

• Rafferty Asset Management LLC decreased its stake in Insulet Corporation by 25.8%, holding 6,495 shares valued at approximately $1.71 million.
• Insulet reported a strong quarterly earnings performance with an EPS of $1.17, surpassing estimates by $0.25, along with a 32.9% year-over-year revenue increase.
• The company's stock has received multiple upgrades from analysts, with a consensus rating of "Moderate Buy" and a target price of $332.71.

Rafferty Asset Management LLC decreased its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 25.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,495 shares of the medical instruments supplier's stock after selling 2,261 shares during the quarter. Rafferty Asset Management LLC's holdings in Insulet were worth $1,706,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Caisse DE Depot ET Placement DU Quebec lifted its position in Insulet by 169.1% in the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 43,372 shares of the medical instruments supplier's stock worth $11,390,000 after buying an additional 27,254 shares during the last quarter. Corebridge Financial Inc. raised its stake in shares of Insulet by 12.2% in the first quarter. Corebridge Financial Inc. now owns 20,844 shares of the medical instruments supplier's stock valued at $5,474,000 after acquiring an additional 2,266 shares during the period. Kayne Anderson Rudnick Investment Management LLC lifted its holdings in shares of Insulet by 1,316.5% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier's stock worth $50,818,000 after acquiring an additional 179,850 shares during the last quarter. Synovus Financial Corp boosted its stake in shares of Insulet by 45.4% during the 1st quarter. Synovus Financial Corp now owns 4,310 shares of the medical instruments supplier's stock worth $1,132,000 after purchasing an additional 1,346 shares during the period. Finally, Jump Financial LLC grew its holdings in Insulet by 3,824.3% during the 1st quarter. Jump Financial LLC now owns 59,100 shares of the medical instruments supplier's stock valued at $15,520,000 after purchasing an additional 57,594 shares during the last quarter.

Insulet Stock Up 0.8%

PODD stock traded up $2.83 during trading on Thursday, hitting $346.36. 230,311 shares of the company's stock traded hands, compared to its average volume of 753,441. The firm has a market capitalization of $24.38 billion, a P/E ratio of 105.28, a PEG ratio of 2.85 and a beta of 1.36. Insulet Corporation has a 1 year low of $211.27 and a 1 year high of $350.00. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The business has a fifty day simple moving average of $306.11 and a two-hundred day simple moving average of $288.90.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business's revenue was up 32.9% compared to the same quarter last year. During the same period last year, the business posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. The Goldman Sachs Group started coverage on Insulet in a research report on Friday, May 30th. They set a "buy" rating and a $380.00 target price for the company. Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target for the company in a research note on Tuesday, May 13th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Wells Fargo & Company lifted their target price on Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Finally, Oppenheimer boosted their target price on shares of Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Sixteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $332.71.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.